Encore Opportunities: What Really Changes After the Series C Expansions

What Actually Changes After the Series C Expansions

The main article argued that Encore’s old problem, turning accounting income into cash, partially cleared in 2025. This follow-up isolates the next question: what happens to that cash after three decisions collided almost at once, a $74 million distribution to the shareholder, a more aggressive move into new investment verticals, and two quick Series C tap issues in November 2025 and January 2026.

The key point is that the Series C expansions did not solve an immediate liquidity problem. By year-end 2025, consolidated cash already stood at $74.9 million and the company was far inside its bond covenants. What they did do was expand management’s room to act very quickly. The story is no longer whether Encore can refinance. It is whether the new cash will increase repayment capacity faster than it increases capital-allocation experimentation.

Four points matter immediately:

• The company generated real cash in 2025, but it did not keep most of it on the balance sheet. Cash flow from operating activity reached $154.2 million, while the same year included a $74 million dividend to the shareholder and $12.4 million of distributions to non-controlling interests.
• The issuer-layer picture is sharper. In the parent-only statement, cash flow from operating activity reached $170.3 million, but financing cash flow still ended negative at $11.0 million even after $94.1 million of net bond issuance, mainly because $74 million went out to owners and $29.6 million was paid in bond principal.
• Series C expanded very quickly. Its nominal balance stood at NIS 320.7 million at the end of 2025 and at NIS 514.7 million by the report date.
• The credit market provided access, not a blank check. In January 2026 Midroog kept the rating at Baa1.il stable even as the tap limit was raised from NIS 150 million to NIS 210 million, but it also repeated that the collateral of series B and C does not justify rating uplift.

The Right Lens Is the Issuer Cash Box, Not Only the Consolidated View

On the consolidated level, 2025 looks fairly comfortable. Cash rose from $20.9 million to $74.9 million, investing cash flow was negative $68.7 million, and financing cash flow was negative $31.4 million. Anyone stopping there could conclude that the company already built a sufficient cushion and that the Series C taps were mainly an extra layer of convenience.

The parent-only statement gives the more relevant picture for bondholders. This is the layer that issues the debt, pays the shareholder dividend, and decides where cash moves up and where it moves down.

This chart explains why the Series C taps are first and foremost a capital-allocation story. At the issuer layer, cash did rise, but the funding did not just build a cash reserve. The $94.1 million of net bond issuance ran into the same year’s $74 million of owner distributions, $29.6 million of bond principal payments, and $10.9 million of interest paid. Put simply, a large part of the new debt did not remain upstairs. It was absorbed almost immediately into distributions and refinancing.

This is not an immediate liquidity red flag. The covenants themselves are very far from tight, and the company still ends the year with $58.8 million of parent cash and $74.9 million of consolidated cash. But it does sharpen the thesis: the Series C expansions increased management flexibility faster than they increased bondholder margin of safety.

2025 Had Already Used Up Part of the Air, Before January 2026

The right framing here is all-in cash flexibility. The question is not how much EBITDA the business can produce before management decisions. The question is how much cash remains after the actual uses of cash.

The 2025 numbers line up almost like a classic discipline test:

• Cash flow from operating activity: $154.2 million
• Investing cash flow: negative $68.7 million
• Dividend to the shareholder: $74.0 million
• Distributions to non-controlling interests: $12.4 million
• Bond principal repayment: $29.6 million
• Lease cash payments: $5.8 million
• Interest paid: $13.6 million
• Net bond issuance plus minority investment: $103.9 million

This is the core of the debate. The company produced strong operating cash flow, but in the same year it also chose to distribute cash out, repay debt, and push money into new activities. So January 2026 did not arrive at an empty company, but it did arrive at a company that had already decided that 2025 cash would not simply sit still on the balance sheet.

The second part of the story is where the money had already started moving. In convenience stores and travel centers, investments in equity-accounted companies reached $48.1 million. In HUD financing, the company put up $8.9 million of net deposits in December 2025 to support guarantees, at a 12% return, and added another roughly $2.3 million of net preferred financing at a 15% return. After the balance-sheet date, another roughly $3.7 million of deposits and $5.75 million of preferred financing were added.

This is exactly where the credit question changes. If 2025 was the proof year that the core can generate cash, late 2025 and early 2026 show that management is already trying to allocate that cash outside the SEC and P4D core before a long operating track record exists in the new activities.

What the Market Bought in January 2026, and What It Still Did Not Buy

The bond market gave Encore two different answers almost at the same time.

The first answer was very positive on access. In November 2025 the company issued NIS 190.731 million par value of Series C and received NIS 198.475 million of gross proceeds. In January 2026 it received 74 orders for NIS 223.235 million of par value, but capped the issuance at NIS 210 million and allocated pro rata at 94.07%. Put simply, the market was open.

The second answer was much more cautious. On January 12, 2026 Midroog assigned Baa1.il stable to a Series C tap of up to NIS 150 million par, and on January 13 it updated the same action to up to NIS 210 million. In both cases, the stated use of proceeds was mergers and acquisitions. In that same report, Midroog repeated that it was not granting structural rating uplift to the collateral of series B and C because the collateral quality does not meet the threshold for “medium and above” quality.

That wording matters. The credit market is saying two things at once: it believes the company can raise more money, and it is not willing to say that the collateral itself has made the risk materially safer. So January 2026 is not only a liquidity approval. It is also a reminder that bondholders are still relying first on allocation quality and cash-flow quality, not on collateral magic.

Why This Matters for the Credit Structure

Series C has a clear collateral package: a first-ranking pledge on the shares of Surepoint Medical Holdings, LLC, which holds the emergency-care activity, and on all cash flows generated from it. At the end of 2025, the series had NIS 320.731 million of par outstanding, a fair value in the statements of NIS 325.823 million, and a market value of NIS 335.132 million. By the report date, par outstanding had already risen to NIS 514.694 million.

From a covenant perspective, the company looks very far from stress. Equity stood at $158.2 million against a $40 million floor. Adjusted net financial debt to adjusted EBITDA stood at 0.26 against a 5.5 ceiling. Even the step-up triggers, $50 million of equity, leverage of up to 3.5, and adjusted EBITDA above $30 million, look comfortably distant. The company also stated explicitly that it has no hedging transactions in connection with the bond issuance.

That is exactly why the issue here is not immediate financial pressure. It is the quality of the next decision. January 2026 proceeds were earmarked for mergers and acquisitions, while the Series C collateral remained tied to SEC and its cash flows. That means the debt load is certainly larger, but credit quality will improve only if the new capital starts creating additional cash engines quickly enough and with sufficient quality. This report does not yet show that.

That is also why the absence of rating uplift matters so much. If even after a Baa1.il stable rating Midroog is not willing to translate the collateral into a better rating layer, then the focus for bondholders has shifted from “is there collateral” to “does management know how not to overload collateral that already exists.”

Conclusion

The Series C expansions changed Encore less at the level of immediate liquidity and more at the level of the discipline it will now be required to show. 2025 already proved the company can generate cash. November 2025 and January 2026 proved that the bond market is also willing to keep funding it. But those two facts are not the same thing as building a stronger credit profile.

Bottom line: after Series C, Encore looks less like a company still trying to prove the model works and more like a company that now has to prove it knows when to stop. If the new cash is directed into transactions that earn above the cost of debt without weakening Series C holders’ dependence on SEC, January 2026 will look, in hindsight, like a successful expansion of strategic room. If the new war chest simply enables more distributions and more moves into unproven areas, January 2026 will look like the point at which allocation risk rose faster than credit quality.